Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Basic, Translational & Therapy

Ac-225-DOTATOC - an empiric dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors

Clemens Kratochwil, Frank Bruchertseifer, Frederik Giesel, Christos Apostolidis, Uwe Haberkorn and Alfred Morgenstern
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1232;
Clemens Kratochwil
1Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Bruchertseifer
2Institute for Transuranium Elements, European Commission, Joint Research Centre, Karlsruhe, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederik Giesel
1Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christos Apostolidis
2Institute for Transuranium Elements, European Commission, Joint Research Centre, Karlsruhe, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uwe Haberkorn
1Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alfred Morgenstern
2Institute for Transuranium Elements, European Commission, Joint Research Centre, Karlsruhe, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1232

Objectives There are no established dosimetry tools to predict toxicity of “targeted alpha-therapy” (TAT), yet. We conducted an empiric dose escalation to find the maximum tolerable dose (MDT) of single cycle and fractionation concepts for Ac-225-DOTATOC radionuclide therapy.

Methods According to Declaration of Helsinki’s “Unproven interventions in Clinical Practice” we performed 46 treatment cycles in 34 patients with progressive neuroendocrine tumors (NET). After each cycle acute toxicity was documented according to CTCAE criteria. First observations are also available for chronic kidney toxicity as the follow up for the first 17 patients has now reached 2 years.

Results The MTD of a single cycle Ac-225-DOTATOC was considered to be 40 MBq. Multiple fractions were tolerated with 25 MBq every 4 months or 18.5 MBq every 2 months. Cumulative activities of 75 MBq were found tolerable in regard to delayed toxicity. The radiologic treatment response that was observed in some patients is without clear preference of a particular fractionation concept until now.

Conclusions We present a well tolerable treatment protocol for TAT with Ac-225-DOTATOC in NET patients that also demonstrated promising treatment efficacy in various patients. If TAT provides general advantages in comparison to beta emitter based radionuclide therapy cannot be derived from the available data, yet. Comparative trials are needed in the future.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 56, Issue supplement 3
May 1, 2015
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Ac-225-DOTATOC - an empiric dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Ac-225-DOTATOC - an empiric dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors
Clemens Kratochwil, Frank Bruchertseifer, Frederik Giesel, Christos Apostolidis, Uwe Haberkorn, Alfred Morgenstern
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1232;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Ac-225-DOTATOC - an empiric dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors
Clemens Kratochwil, Frank Bruchertseifer, Frederik Giesel, Christos Apostolidis, Uwe Haberkorn, Alfred Morgenstern
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1232;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Basic, Translational & Therapy

  • Clinical implication of preablation thyroglobulin level in differentiated thyroid carcinoma patients underwent recombinant human thyrotropin aided ablative radioiodine treatment
  • Optimizing PET/MRI Y-90 post-therapy imaging using PET/CT as a standard
  • Association between iodine intake and treatment outcomes dioiodine remnant ablation in patients with papillary thyroid cancer
Show more Oncology: Basic, Translational & Therapy

MTA I: Radiopharmaceutical Therapy Posters

  • Ac-225-PSMA617 - a single center experience of 40 patients receiving PSMA-targeted Alpha therapy
  • Low dosage 177LuDOTATATE (177LuPRRT) re-treatment in GEP-NEN patients who relapse after 177LuPRRT
  • Anlysis of clinical factors related with successful ablation following rhTSH aided radioiodine ablation for well differentiated thyroid cancer.
Show more MTA I: Radiopharmaceutical Therapy Posters

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire